News
Beren Therapeutics Announces U.S. FDA Approval of LEMBAZ™ (adrabetadex), First & Only Medicine to Improve Survival in Infantile-Onset Niemann-Pick Disease, Type C
November 17, 2026
Beren Therapeutics Presents New Adrabetadex Data Showing Preservation of Neurological Function for More Than 10 Years in Children with Infantile-Onset NPC
October 15, 2026
Press Release
Beren Therapeutics Launches ‘Test for NPC’ to Help Identify People with Niemann-Pick Disease, Type C Who Remain Undiagnosed
September 9, 2026
Press Release
Beren Therapeutics Expands Cyclodextrin Intellectual Property Estate with Eight New U.S. Issued Patents
August 6, 2026
Press Release
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
June 10, 2026
Press Release
Beren Therapeutics Announces Six Presentations at the 2026 Ara Parseghian Medical Research Fund (APMRF) Conference
May 29, 2026
Press Release
Beren Therapeutics Announces FDA Extension of Review Period for New Drug Application (NDA) for Adrabetadex for the Treatment of Infantile-Onset Niemann-Pick Disease, Type C
May 28, 2026
Press Release
Beren Therapeutics Presents Data Supporting the Efficacy of Adrabetadex in Infantile-Onset NPC at 2026 ACMG Clinical Genetics Meeting
March 12, 2026
Press Release
Beren Therapeutics Announces FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann Pick Disease Type C
February 23, 2026
Press Release
Beren, Through its Subsidiary Mandos, Submits New Drug Application to U.S. FDA for Adrabetadex in Infantile-Onset NPC
December 19, 2025
Press Release